Full Breakdown
Federal Charges Against ExThera Medical Executive Over Patient Deaths
3/6/2026, 6:55:35 AM
Overview of the Charges
Federal prosecutors have charged Dr. Sanja Ilic, the former chief regulatory officer of ExThera Medical, with concealing the deaths of two cancer patients who underwent treatment with the company's blood filter. The Justice Department announced that Dr. Ilic has agreed to plead guilty and could face up to three years in prison. In addition, ExThera has entered into a deferred prosecution agreement, admitting to defrauding and misleading the Food and Drug Administration (FDA) by failing to report these fatalities.
Details of the Case
The two patients, David Hudlow from Panama City, Florida, and Kyle Chupp from Orillia, Ontario, died one day apart in April 2024 after receiving treatment on the Caribbean island of Antigua. They were part of a group of late-stage cancer patients who were attracted to ExThera's treatment, which had only received conditional FDA approval for Covid-19 treatment. Each patient was charged $45,000 per treatment session. The operation was initiated by Alan Quasha, an American billionaire and investor in ExThera, through his family-owned private equity firm, Quadrant Management.
ExThera's blood filter was promoted as a potential cure for cancer, with Dr. Ilic and board member John Preston actively marketing it to patients in the United States and Canada. While both Quasha and Preston have denied any wrongdoing, they have not faced charges in connection with the case. The investigation is ongoing, led by the New England Strike Force of the Justice Department’s Health Care Fraud Unit.
Financial Implications for ExThera
As a consequence of the charges, ExThera has agreed to pay a criminal penalty of $750,000, which will be allocated to the families of the deceased patients, and to forfeit $5.7 million. The company, which once employed around 50 individuals, is reportedly seeking new investments and is nearing a Chapter 11 bankruptcy reorganization, according to investment pitch documents obtained by The New York Times.
Criticism and Opposition
The actions of ExThera and its executives have drawn scrutiny, particularly regarding the ethical implications of promoting a treatment that had not been fully approved for cancer patients. Critics argue that the company exploited vulnerable individuals seeking hope in their battle against terminal illness.
Official Statements
The Justice Department has emphasized the seriousness of the charges against Dr. Ilic and the implications for ExThera's operations. The ongoing investigation aims to ensure accountability for the actions taken by the company and its executives.
What's Next
The investigation into ExThera Medical continues, with potential further legal actions against other individuals involved in the promotion and administration of the blood filter treatment. The outcome of Dr. Ilic's plea agreement and the company's bankruptcy proceedings will also be closely monitored.
